{
  "docId": "019dd923-5e88-73ef-bd5a-c8877c2d773b",
  "docSlug": "62a053437732d31d",
  "documentTitle": "250114 FRE prsn JPM SFO 0",
  "authorId": "JPMorgan",
  "authorName": "Fresenius",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 9,
  "pageCount": 15,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "geographic_map",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "Includes map of US with icons for production and distribution sites.",
  "elementsJson": [
    "headline_text",
    "map",
    "icon_grid",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-c8877c2d773b/9",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-c8877c2d773b",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-c8877c2d773b.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-c8877c2d773b#slide-9",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "A market leader with >900m units shipped in the U.S. and 700+ SKUs in the portfolio.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-28a9-71be-806d-7449ac0e972f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.038,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "1 2022-2023 data on file 2 2023 data on file 3 During the first half of 2022, data on file",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c5be1db-4b2c-45f6-a716-a100ea81cdab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.56,
        "x": 0.038,
        "y": 0.15
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e964d02-0da7-42c7-9754-3ab6af1de783",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.08,
        "x": 0.038,
        "y": 0.84
      },
      "kind": "legend",
      "text": "Production Distribution",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afba3a74-000f-4d6b-acb7-1729fbc19fe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.33,
        "x": 0.63,
        "y": 0.44
      },
      "kind": "list",
      "text": "A market leader with >900m units shipped in the U.S. and 700+ SKUs in the portfolio; More than 70% of Kabi’s pharmaceuticals for the U.S. are formulated, filled and packaged in the U.S.; More than 70% of the units shipped in the U.S. are on the FDA’s Essential Medicines List; Nearly $1bn invested in US-based production and distribution capacities; Growing and investing in latest technologies and forward-thinking innovations to expand access and affordability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ff01274-7cf9-4991-9a46-0166723fa05e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "units shipped: >900m",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-28a9-71be-806d-7afc71d5bd45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.151,
        "w": 0.267,
        "x": 0.038,
        "y": 0.056
      },
      "kind": "title",
      "text": "Fresenius Kabi More in America",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1684294e-f3d4-4272-afc2-c4f204e42339",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 8,
      "beatId": "96ffe88c-8d2a-4d23-a98c-19240d899804",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 8-12 provide data and metrics on Fresenius Kabi's momentum, growth, and financial progression.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "0f7b9246-98b4-450f-9b9b-af0a2ddf2192",
      "evidence": "Slides 6-10 emphasize the need for transformation and growth.",
      "position": 0,
      "objective": "Highlighting the importance of transformation",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}